A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 1 in Healthy Infants
Latest Information Update: 05 Nov 2021
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors Merck Sharp & Dohme Corp.
- 24 Jun 2020 Results published in the Pediatric Infectious Disease Journal
- 08 May 2019 According to a Merck & Co media release, results form this trial were presented during an oral session at the 37th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia.
- 08 May 2019 Results presented in the Merck & Co media release.